Roche Driving PROGRESS in Treatment of Difficult-to-Cure Hepatitis C Patients With New PEGASYS (R) (peginterferon alfa-2a (40KD)) and COPEGUS(R) (ribavirin) Trial
Basel, Switzerland (ots/PRNewswire) - - New International Trial Called PROGRESS Starts in 15 Countries Roche today announces the start of a large multinational trial in patients with difficult-to-cure genotype 1 hepatitis C. This international study will evaluate the effect of PEGASYS (peginterferon ...